ß-blocker timolol prevents arrhythmogenic Ca²⁺ release and normalizes Ca²⁺ and Zn²⁺ dyshomeostasis in hyperglycemic

Erkan Tuncay1, Esma N Okatan, Guy Vassort

  • 1Department of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.

Plos One
|August 8, 2013
PubMed

Insights

Beta-blocker timolol protects diabetic rat hearts by normalizing calcium handling and reducing oxidative stress. This treatment improves cardiac function and cellular electrical activity, preventing diabetic heart dysfunction.

Area of Science:

  • Cardiovascular Science
  • Diabetology
  • Pharmacology

Background:

  • Diabetes mellitus causes defective cardiac mechanical activity due to impaired intracellular calcium (Ca2+) handling and increased oxidative stress.
  • Beta-blockers, like timolol, show cardioprotective effects by scavenging free radicals and acting as antioxidants.

Purpose of the Study:

  • To investigate the cardioprotective mechanisms of beta-blocker timolol in diabetic rats.
  • To elucidate how timolol treatment normalizes intracellular Ca2+ handling and redox status in the diabetic heart.

Main Methods:

  • Diabetic rats were treated with timolol for 12 weeks.
  • Cardiac function, cardiomyocyte electrical activity, and Ca2+ handling (including Ca2+ transients and sparks) were assessed.
  • Protein levels of key Ca2+ handling regulators (RyR2, calstabin2, NCX, pPLN/PLN) and cellular redox status were analyzed via Western blot.

Main Results:

  • Timolol treatment prevented diabetes-induced depression in left ventricular contractility and attenuated cardiomyocyte hypertrophy.
  • Timolol normalized Ca2+ transient kinetics, reduced sarcoplasmic reticulum Ca2+ loading, and corrected basal intracellular Ca2+ and Zn2+ ([Ca2+]i and [Zn2+]i) levels.
  • Treatment antagonized ryanodine receptor 2 (RyR2) hyperphosphorylation, restored RyR2 and calstabin2 levels, and normalized NCX and pPLN/PLN ratios.
  • Timolol balanced oxidant/antioxidant levels, preventing altered cellular redox state in the diabetic heart.

Conclusions:

  • Timolol exerts cardioprotection in diabetic rats by normalizing the RyR2 macromolecular complex and Ca2+ handling regulators.
  • The protective effect is linked to preventing Ca2+ leak and restoring [Ca2+]i and [Zn2+]i homeostasis, partly via controlling cellular redox status.
  • Timolol offers a potential therapeutic strategy for diabetic cardiomyopathy by addressing both Ca2+ dysregulation and oxidative stress.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...